Alterations in central memory and effector cytotoxic T cells after initiation of pomalidomide, ixazomib, dexamethasone. Peripheral blood samples taken at day 1 (before treatment), and day 15 (after 2 weeks of pomalidomide, ixazomib, and dexamethasone) were analyzed by flow cytometry to identify changes in the immune subsets associated with treatment. Relative percentages of central memory cytotoxic T cells were increased, whereas the effector cytotoxic T-cell percentage fell after initiation of therapy. Ixa-Pom, ixazomib, pomalidomide.